---
schema_version: "secwatch.filing_event.v1"
accession: "0000926617-23-000083"
form_type: "8-K"
ticker: "AWHL"
cik: "0000926617"
company_name: "Aspira Women's Health Inc."
filed_at: "2023-10-13T23:59:59+00:00"
generated_at: "2026-06-10T00:28:35.469381+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Aspira Women's Health to restate 2022 and Q3 2022 financials due to warrant accounting error

## Summary
- Warrant liability fair value corrected from $7.75M to $3.98M, a $3.77M overstatement.
- Offering cost allocation adjusted: $543K moved from G&A expense to equity; $574K reclassified to non-operating expense.
- Material weakness identified in internal control over financial reporting related to complex transaction accounting.
- Error has no effect on cash, cash equivalents, or revenues; cash flow classification also corrected.
- Company will amend 2022 10-K and restate Q3 2022 10-Q; steps underway to remediate controls.

## SEC filing metadata
- accession: 0000926617-23-000083
- form_type: 8-K
- ticker: AWHL
- cik: 0000926617
- company_name: Aspira Women's Health Inc.
- filed_at: 2023-10-13T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 4.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/926617/000092661723000083/0000926617-23-000083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/926617/000092661723000083/awh-20231013x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000926617-23-000083
- JSON: https://secwatch.observer/filing/0000926617-23-000083.json
- Plain text: https://secwatch.observer/filing/0000926617-23-000083.txt

## Key facts
- Auditor Changes
  Aspira Women's Health Inc. reported that prior financial statements should not be relied upon.
  - Action: non reliance
  source text: the Audit Committee of the Board of Directors (the “Audit Committee”) of Aspira Women’s Health Inc. (the “Company”) and the Company’s management determined that its previously issued financial statements in its Annual Report on Form 10-K for the year ended December 31, 2022, as well as the previously filed Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022 (collectively, the “Prior Period Financial Statements”), should be restated and should no longer be relied upon
  evidence_url: https://www.sec.gov/Archives/edgar/data/926617/000092661723000083/0000926617-23-000083-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.